Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC)

Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC) - Inhibition of virus induced Aggravation of childhood asthma by Salmeterol/Fluticasone Propionate Combination(SFC)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023224

Enrollment

Registered

2016-08-01

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

We will give Fluticasone for 12 weeks. We will give SFC for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Physician diagnosed asthma( More than 3 wheeze episode) More than 2 asthma attacks for 8 weeks LTRA is taken for more than 1month as a controller

Exclusion criteria

Exclusion criteria: SFC or Fluticasone is used as a controller Patients has respiratory diseases except asthma

Design outcomes

Primary

Measure	Time frame
In patients with a common cold, asthma control was significantly more effective for those treated with SFC compared to treatment with Fluticasone	—

Secondary

Measure	Time frame
In 12th week SFC group will show higher Best ACT P score and QOL score than Fluticasone group. SFC group will less freqently to use beta stimulator and less frequently to visit ER department.	—

Countries

Japan

Contacts

Public ContactDaisuke Hayashi

Tsukuba Medical Center Hospital Department of Pediatrics

hayashi_daisuke@tmch.or.jp029-851-3511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026